MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-14
CAS:<p>HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.</p>Formula:C24H23FN6O2Color and Shape:SolidMolecular weight:446.48pan-Raf/RTK inhibitor 1
CAS:<p>Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.</p>Formula:C29H28F3N7O3Color and Shape:SolidMolecular weight:579.573SOS1-IN-10
<p>SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).</p>Formula:C22H19F5N4OColor and Shape:SolidMolecular weight:450.4KRAS G12D inhibitor 1
CAS:<p>KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].</p>Formula:C33H32F2N6O2Color and Shape:SolidMolecular weight:582.64p38-α MAPK-IN-5
CAS:<p>p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.</p>Formula:C37H49N11O2Color and Shape:SolidMolecular weight:679.86KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Formula:C29H27ClFN4O2PColor and Shape:SolidMolecular weight:548.98KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106p38α-MK2-IN-1
CAS:<p>p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.</p>Formula:C27H26F3N5O3Color and Shape:SolidMolecular weight:525.522KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Formula:C26H24ClF4N5O3Purity:98%Color and Shape:SolidMolecular weight:565.95PF-03715455
CAS:<p>PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.</p>Formula:C35H34ClN7O3S2Purity:98%Color and Shape:SolidMolecular weight:700.27RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Formula:C27H24F3N7O2Color and Shape:SolidMolecular weight:535.52PS-166276
CAS:<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Formula:C20H30N8OColor and Shape:SolidMolecular weight:398.51Luvometinib
CAS:<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Formula:C26H22F2IN5O4SColor and Shape:SolidMolecular weight:665.45KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68FMK-MEA
CAS:<p>FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.</p>Formula:C21H26FN5O2Purity:98%Color and Shape:SolidMolecular weight:399.46KRAS G12D inhibitor 26
CAS:<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Formula:C35H44ClFN8O2Purity:99.93%Color and Shape:SolidMolecular weight:663.23SR-302
CAS:<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Formula:C32H42N6O5SColor and Shape:SolidMolecular weight:622.778(R)-STU104-d6
CAS:<p>(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.</p>Formula:C18H182D6O4Color and Shape:SolidMolecular weight:304.37MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Formula:C33H33FN6O2Color and Shape:SolidMolecular weight:564.65KRASG12C IN-15
CAS:<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Formula:C31H32FN3O2Color and Shape:SolidMolecular weight:497.603KRAS G12C inhibitor 37
CAS:<p>KRAS G12C inhibitor 37 targets a key signaling protein, showing promise for cancer research involving KRAS G12C.</p>Formula:C35H39F3N8O2Color and Shape:SolidMolecular weight:660.73(rel)-AR234960
CAS:<p>(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.</p>Formula:C27H30FN5O5SColor and Shape:SolidMolecular weight:555.63p38 MAPK-IN-6
CAS:<p>p38 MAPK-IN-6 (compound c47) is an inhibitor of p38 MAPK, exhibiting a 14% inhibition rate at a concentration of 10 μM.</p>Formula:C16H14BrN3OS2Color and Shape:SolidMolecular weight:408.336JH295 hydrate
<p>JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.</p>Formula:C18H18N4O3Color and Shape:SolidMolecular weight:338.36JD118
CAS:<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>Formula:C13H12N4S2Color and Shape:SolidMolecular weight:288.391JNK-1-IN-5
CAS:<p>JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.</p>Formula:C23H21BrN6O3Color and Shape:SolidMolecular weight:509.355XMU-MP-9
CAS:<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Formula:C19H13ClFN3OSColor and Shape:SolidMolecular weight:385.84SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Formula:C26H28ClFN6Color and Shape:SolidMolecular weight:478.992p38 Kinase inhibitor 8
CAS:<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Formula:C22H21FN6O2Color and Shape:SolidMolecular weight:420.44p38α inhibitor 8
CAS:<p>p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.</p>Formula:C17H13FN6Color and Shape:SolidMolecular weight:320.324p38 Kinase inhibitor 7
CAS:<p>p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.</p>Formula:C22H25FN6OColor and Shape:SolidMolecular weight:408.472Coelogin
CAS:<p>Coelogin is an orally effective bone-protective agent that activates ER-Erk and Akt-dependent signaling pathways, thereby stimulating osteoblast differentiation. It is utilized in osteoporosis research.</p>Formula:C17H16O5Color and Shape:SolidMolecular weight:300.31p38 MAP Kinase-IN-1
CAS:<p>p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.</p>Formula:C20H19FN6OColor and Shape:SolidMolecular weight:378.403JNK-IN-19
CAS:<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>Formula:C22H24F3N6Na2O6PColor and Shape:SolidMolecular weight:602.41(±)-Perillaldehyde
CAS:<p>(±)-Perillaldehyde exhibits antidepressant effects in mice with stress-induced depressive-like behavior by modulating the olfactory nervous system. Additionally, it demonstrates anti-inflammatory activity by activating JNK in RAW264.7 cells and suppressing the expression of TNF-α, with an IC50 value of 171.7 μM.</p>Formula:C10H14OColor and Shape:SolidMolecular weight:150.22RIPK2-IN-6
CAS:<p>RIPK2-IN-6 (Compound 15a) is an inhibitor of RIPK that specifically targets the phosphorylation of RIPK2, thereby suppressing the NF-κB and MAPK signaling pathways. It has demonstrated anti-inflammatory and anti-fibrotic activities in a mouse model of colitis induced by Dextran sodium sulfate.</p>Formula:C26H21NO3Color and Shape:SolidMolecular weight:395.45Lambertellin
CAS:<p>Lambertellin, an effective antibiotic, acts as both a bactericide and fungicide. It exerts anti-inflammatory effects in LPS-stimulated RAW 264.7 macrophages by modulating the activation of MAPK and NF-κB signaling pathways.</p>Formula:C14H8O5Color and Shape:SolidMolecular weight:256.21Casein kinase 1δ-IN-27
CAS:<p>Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.</p>Formula:C21H19FN6Color and Shape:SolidMolecular weight:374.414JNK-IN-21
CAS:<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>Formula:C19H16N2O2SColor and Shape:SolidMolecular weight:336.408KRAS G12C inhibitor 15
CAS:<p>KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .</p>Formula:C25H21ClF2N4O3Purity:98%Color and Shape:SolidMolecular weight:498.91CK1δ-IN-9
CAS:<p>CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.</p>Formula:C16H12FN5Color and Shape:SolidMolecular weight:293.298p38-α MAPK-IN-10
CAS:<p>p38-α MAPK-IN-10 (Compound 6) is an inhibitor of p38α, with an IC50 value of 4 nM.</p>Formula:C27H34Cl2N6Color and Shape:SolidMolecular weight:513.505p38-α MAPK-IN-9
CAS:<p>p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor with a Ki value of 0.057 nM. It effectively inhibits LPS-induced TNFα production in hPBMC cells, exhibiting an IC50 of 18 nM.</p>Formula:C19H20N8O2Color and Shape:SolidMolecular weight:392.414Casein kinase 1δ-IN-31
CAS:<p>Casein kinase1δ-IN-31 (Compound 16) is an inhibitor of casein kinase (CK), specifically targeting CK1α, CK1δ, and p38α, with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, Casein kinase1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM.</p>Formula:C17H13FN4Color and Shape:SolidMolecular weight:292.31pan-KRAS-IN-17
CAS:<p>pan-KRAS-IN-17 (Example 34) is an inhibitor that targets multiple forms of the KRAS protein.</p>Formula:C34H33F3N5O8PColor and Shape:SolidMolecular weight:727.623AM-001
CAS:<p>AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.</p>Formula:C24H16FN3OS2Color and Shape:SolidMolecular weight:445.53J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Formula:C38H32N2O12Purity:98%Color and Shape:SolidMolecular weight:708.67KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Formula:C32H33ClFN7O3Color and Shape:SolidMolecular weight:618.10KRAS G12C inhibitor 20
CAS:<p>KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.</p>Formula:C33H37ClFN7O3Color and Shape:SolidMolecular weight:634.14
